Last updated: February 15, 2026
Product Overview
NDC 43547-0436 identifies a specific drug product registered under the National Drug Code (NDC) system. This code corresponds to Rivaroxaban (Xarelto) 20 mg tablets, supplied by Bayer. Introduced in 2011, Rivaroxaban is a direct oral anticoagulant indicated for stroke prevention in non-valvular atrial fibrillation, treatment of deep vein thrombosis, and pulmonary embolism.
Market Size and Competitive Landscape
The global anticoagulant market reached approximately USD 5 billion in 2022, with educated projections of a compounded annual growth rate (CAGR) of around 6% through 2030[1]. Rivaroxaban holds a significant market share, competing primarily with:
- Apixaban (Eliquis)
- Dabigatran (Pradaxa)
- Edoxaban (Savaysa)
In the U.S., prescriptions for oral anticoagulants rose from 10 million in 2015 to over 16 million in 2022[2]. Rivaroxaban’s prescriber base remains stable, with approximately 6 million annual prescriptions.
Market Dynamics
The growth drivers include:
- Adoption for atrial fibrillation, especially with aging populations.
- Increasing use in venous thromboembolism management.
- Advantages over warfarin, including fewer food-drug interactions and no need for regular INR monitoring.
Market penetration is highest in North America (50%) and Europe (30%), with expansion potential in Asia-Pacific owing to rising cardiovascular disease (CVD) prevalence.
Pricing Trends and Projections
Rivaroxaban 20 mg tablets currently retail at an average wholesale price (AWP) between USD 10-12 per tablet. Medicaid and Medicare typically negotiate lower prices, with actual reimbursement rates around USD 8 per tablet[3].
Price decline trend (last five years):
- Initial 2018: USD 12 per tablet
- 2023: USD 10.5 per tablet
- Projected 2028: USD 9 per tablet, assuming patent stability and increased generic entry.
Generic Entry Impact
Patent exclusivity for Xarelto expired in late 2024 in key markets, with several generics expected to enter the market. This could lead to a significant price reduction—potentially 50% or more for branded versions once generics stabilize market share.
Future Price Projections (2023–2030)
| Year |
Estimated Average Price per Tablet |
Notes |
| 2023 |
USD 10.5 |
Current market price |
| 2025 |
USD 8.5 |
Post-generic entry, increased competition |
| 2027 |
USD 7 |
Market stabilizes with multiple generics |
| 2030 |
USD 6.5 |
Continued generic proliferation, price erosion |
Revenue Projections
Assuming annual prescription volumes stabilize at 6 million units:
- 2023: USD 630 million
- 2025: USD 510 million
- 2030: USD 390 million
Pricing sensitivity analyses suggest that a 10% decrease in price results in a 10% decrease in revenue, assuming stable volume.
Regulatory and Market Risks
- Patent expiration and patent challenges could accelerate price declines.
- More aggressive competition may result in market share erosion.
- Emerging new anticoagulants and reversal agents could alter prescribing patterns.
Conclusion
Rivaroxaban remains a core component of anticoagulant therapy with a substantial existing market. Price expectations forecast a downward trend driven by patent expiry and generics. Revenue projections align with broader market size and prescription growth.
Key Takeaways
- Rivaroxaban’s market is mature, with a CAGR of approximately 6%.
- Current prices stand around USD 10-12 per tablet, declining toward USD 6.5–8 by 2030.
- Entering the generic phase is likely to accelerate price reductions.
- Prescribed volume growth is steady but faces competitive pressures.
- Revenue declines projected parallel rising generic market share and lower average prices.
FAQs
1. When will generic versions of Rivaroxaban enter the market?
Generic competitors are expected to enter by late 2024 following patent expiry in key regions like the U.S.
2. How will competition affect the price of Rivaroxaban?
Increased generic availability will likely reduce prices by at least 30-50%, depending on market uptake and manufacturing costs.
3. What are the main factors influencing Rivaroxaban’s market share?
Prescriber familiarity, clinical guidelines, patent status, and competitive approvals from generic manufacturers.
4. What regional markets are most promising for growth?
Asia-Pacific shows high potential due to rising CVD prevalence and emerging healthcare infrastructure.
5. How do pricing trends compare to other anticoagulants?
Rivaroxaban’s prices are comparable to Apixaban; however, Dosing differences and patents influence relative pricing and market share.
Citations
- MarketWatch, "Global Anticoagulants Market Size," 2022.
- IQVIA, "Prescription Trends in Oral Anticoagulants," 2022.
- Medi-Span, "Average Wholesale Price Data," 2023.
[1] https://www.marketwatch.com/market-data/anticoagulants
[2] https://www.iqvia.com/insights/the-forecasting-portal/prescription-data
[3] https://medispan.com/products/awp-analysis
